Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
PacBio Grants Equity Incentive Award to New Employee
11:09pm, Friday, 14'th Feb 2025
MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee o
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall
12:05pm, Friday, 14'th Feb 2025
Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments.
Pacific Biosciences of California, Inc. (PACB) Q4 2024 Earnings Call Transcript
09:09pm, Thursday, 13'th Feb 2025
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance and Investor Relation
Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics
07:01pm, Thursday, 13'th Feb 2025
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key me
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
06:21pm, Thursday, 13'th Feb 2025
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.27 per share a year ago.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
07:20pm, Tuesday, 04'th Feb 2025
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.44, representing a -1.37% change from its previous close.
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
09:05am, Monday, 03'rd Feb 2025
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggier
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025
04:05pm, Thursday, 30'th Jan 2025
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thur
PacBio Announces Appointment of Chris Smith to Board of Directors
09:05am, Thursday, 30'th Jan 2025
PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. PacBio to leverage Chris' extensive expertise in diagnostics and l
PacBio Technology Powers Landmark Multiomic Study Published in Nature Genetics
09:05am, Wednesday, 29'th Jan 2025
New sequencing approach resolves the genetic complexity of a rare Mendelian condition New sequencing approach resolves the genetic complexity of a rare Mendelian condition
PacBio Names Global Institute for Food Security as Canada's First Revio Certified Service Provider
09:05am, Thursday, 23'rd Jan 2025
MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Se
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
12:30pm, Wednesday, 22'nd Jan 2025
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Tuesday, 21'st Jan 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
PACB Stock Declines Despite Promising HiFi Sequencing Findings
01:21pm, Wednesday, 15'th Jan 2025
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
10:01am, Wednesday, 15'th Jan 2025
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.
